Brief: Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy Designation For EDIT-301 For The Treatment Of Severe Sickle Cell Disease
16/10/2023 14:04
Oct 16 (Reuters) - Editas Medicine Inc EDIT.O :
* EDITAS MEDICINE GRANTED FDA REGENERATIVE MEDICINE ADVANCED
THERAPY (RMAT) DESIGNATION FOR EDIT-301 FOR THE TREATMENT OF
SEVERE SICKLE CELL DISEASE
Source text for Eikon: ID:nGNX4ZFLxg
Further company coverage: EDIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Editas Medicine
See all newsEditas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering